Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Leukemia

Free Subscription Articles published in Br J Haematol Retrieve available abstracts of 229 articles: HTML format

Single Articles

September 2025
1. LI X, Zhou Q, Hao X, Cao C, et al
   Targeting NLRP1-CCL8 axis in the leukaemic niche suppresses AML via inhibition of PI3K-AKT signalling.
   Br J Haematol. 2025;207:789-801.
   PubMed     Abstract available
   
   
   
2. CHENG CN, Yang YN, Yeh YH, Chen JS, et al
   The impact of secondary hypogammaglobulinaemia in children with acute lymphoblastic leukaemia receiving maintenance chemotherapy.
   Br J Haematol. 2025;207:892-901.
   PubMed     Abstract available
   
   
   
3. KOSYDAR S, Archibald WJ, Hampel PJ, Call TG, et al
   The role of imaging studies in predicting time to first treatment and overall survival in high-count monoclonal B-cell lymphocytosis.
   Br J Haematol. 2025;207:860-868.
   PubMed     Abstract available
   
   
   
4. ZU Y, Yue X, Zhan X, Liu X, et al
   Secondary malignancies after chronic myeloid leukaemia upon TKI treatment: Population trends and outcomes.
   Br J Haematol. 2025;207:834-841.
   PubMed     Abstract available
   
   
   
5. ROLLES B, Chatain N, Gorg R, Vieri M, et al
   ZIP10 as a potential therapeutic target in acute myeloid leukaemia.
   Br J Haematol. 2025;207:767-779.
   PubMed     Abstract available
   
   
   August 2025
6. TINAJERO J, Ngo D, Motta M, Agrawal V, et al
   The integration of blinatumomab consolidation in the CALGB 10403 regimen for adults with B-cell precursor acute lymphoblastic leukaemia in measurable residual disease-negative remission.
   Br J Haematol. 2025;207:426-431.
   PubMed     Abstract available
   
   
   
7. BORJA-MONTES OF, Toro-Pedroza A, Epperla N, Andritsos LA, et al
   Hairy cell leukaemia and pregnancy: A systematic review and review of literature.
   Br J Haematol. 2025;207:678-682.
   PubMed     Abstract available
   
   
   
8. NACHTKAMP K, Schulz F, Gattermann N, Germing U, et al
   Clinical management of CMML-State of the art.
   Br J Haematol. 2025;207:350-364.
   PubMed     Abstract available
   
   
   
9. SAVONA MR, Odenike O, Roboz GJ, Amin H, et al
   Efficacy and safety of oral decitabine/cedazuridine in the chronic myelomonocytic leukaemia subpopulations from phase 2 and 3 studies.
   Br J Haematol. 2025;207:432-444.
   PubMed     Abstract available
   
   
   
10. KONUMA T, Shimomura Y, Mizuno S, Yamasaki S, et al
    Prognostic factors for allogeneic haematopoietic cell transplantation outcomes in primary refractory acute myeloid leukaemia (2013-2022): A retrospective study by the adult acute myeloid leukaemia working group of the Japanese Society for Transplantat
    Br J Haematol. 2025;207:484-497.
    PubMed     Abstract available
    
    
    
11. XIAO J, Xia Y, Yin F, Shi Z, et al
    Global spatiotemporal distribution characteristics and regional risk stratification model of acute myeloid leukaemia based on molecular genetics and cytogenetic features.
    Br J Haematol. 2025;207:395-406.
    PubMed     Abstract available
    
    
    July 2025
12. YE Y, Liu X, Dai H, Hu J, et al
    Venetoclax plus azacitidine with or without homoharringtonine followed by allogeneic haematopoietic cell transplantation in patients with relapsed/refractory acute myeloid leukaemia: A multicentre cohort study.
    Br J Haematol. 2025;207:151-161.
    PubMed     Abstract available
    
    
    
13. WANG M, Guo Z, Zhao S, Liu L, et al
    CD49d promotes T-cell senescence in chronic lymphocytic leukaemia.
    Br J Haematol. 2025;207:80-91.
    PubMed     Abstract available
    
    
    
14. WILKE AC, Gokbuget N
    The role of blinatumomab in adult acute B lymphoblastic leukaemia.
    Br J Haematol. 2025;207:27-42.
    PubMed     Abstract available
    
    
    
15. LIN ME, Hsu YC, Chiu HL, Yao CY, et al
    Inhibition of DOCK1 suppresses Notch signalling pathway and impairs leukaemogenesis.
    Br J Haematol. 2025;207:59-68.
    PubMed     Abstract available
    
    
    
16. BEHRENS YL, Reinkens T, Hofmann W, Gumann A, et al
    Genomic variant profiling in blast-phase paediatric chronic myeloid leukaemia: Predisposing and driving alterations.
    Br J Haematol. 2025;207:141-150.
    PubMed     Abstract available
    
    
    
17. LUO Y, Fu Y, Kuang M, Wang J, et al
    Ciclosporin A potentiates venetoclax efficacy in FLT3-ITD AML by targeting the NFATC1-AKT-mTOR-BCL-2/MCL-1 signaling axis.
    Br J Haematol. 2025;207:46-58.
    PubMed     Abstract available
    
    
    June 2025
18. AGRAWAL V, Arslan S, Pourhassan H, Koller P, et al
    Hypomethylating agent and venetoclax are effective salvage therapies in relapsed/refractory early T-cell precursor acute lymphoblastic leukaemia.
    Br J Haematol. 2025;206:1678-1682.
    PubMed     Abstract available
    
    
    
19. HEIBLIG M, Plesa A, Tantot J, Jamilloux Y, et al
    Myeloid neoplasm inspired intensive therapy in VEXAS syndrome: A single-centre experience.
    Br J Haematol. 2025;206:1683-1688.
    PubMed     Abstract available
    
    
    
20. HUANG YJ, Liu HC, Kuo MC, Yeh TC, et al
    Frequency and prognostic value of unconventional genetic subtypes in paediatric and young adult B-cell precursor acute lymphoblastic leukaemia in Taiwan.
    Br J Haematol. 2025;206:1699-1709.
    PubMed     Abstract available
    
    
    May 2025
21. AOKI T, Salib M, Suleman A, Ghanem N, et al
    Distinct characteristics and social determinants in adult T-cell leukaemia/lymphoma patients at a tertiary cancer centre in Canada.
    Br J Haematol. 2025 May 6. doi: 10.1111/bjh.20132.
    PubMed     Abstract available
    
    
    
22. SCARADAVOU A
    Cord blood transplants: Advancing leukaemia treatments and addressing health disparities.
    Br J Haematol. 2025;206:1312-1314.
    PubMed     Abstract available
    
    
    
23. ZHENG Z, Wang W, Feng M, Chen X, et al
    The mechanism of EZH2/H3K27me3 downregulating CXCL10 to affect CD8(+) T cell exhaustion to participate in the transformation from myelodysplastic syndrome to acute myeloid leukaemia.
    Br J Haematol. 2025;206:1335-1349.
    PubMed     Abstract available
    
    
    
24. VICENTE-GARCES C, Fernandez G, Esperanza-Cebollada E, Richarte-Franques M, et al
    RNA-sequencing: A reliable tool to unveil transcriptional landscape of paediatric B-other acute lymphoblastic leukaemia.
    Br J Haematol. 2025;206:1355-1365.
    PubMed     Abstract available
    
    
    
25. LIU J, Zhao XS, Chang YJ, Qin YZ, et al
    Monitoring the KMT2A gene post-chemotherapy independently predicts the relapse and survival risk after allogeneic haematopoietic stem cell transplantation.
    Br J Haematol. 2025;206:1418-1429.
    PubMed     Abstract available
    
    
    
26. SUTTORP M, Sembill S, Lensker P, Hildebrand V, et al
    Therapeutic drug monitoring of imatinib in paediatric chronic myeloid leukaemia: Data from a real-world setting.
    Br J Haematol. 2025;206:1397-1405.
    PubMed     Abstract available
    
    
    
27. STASIK S, Eckardt JN, Rollig C, Baldus CD, et al
    The IKZF1 N159S mutation is associated with poor outcome and a distinct molecular profile in adult patients with AML.
    Br J Haematol. 2025;206:1373-1379.
    PubMed     Abstract available
    
    
    April 2025
28. ZHAO C, Xiao MY, Zhang F, Bai L, et al
    Outcomes and prognostic factors associated with relapse after haploidentical stem cell transplantation for paediatric T-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2025;206:1165-1172.
    PubMed     Abstract available
    
    
    
29. CONNERTY P, Xie J, El-Najjar F, Trahair TN, et al
    Immune-deficient MISTRG mice support expansion of leukaemia-initiating cells in xenograft models of paediatric acute myeloid leukaemia.
    Br J Haematol. 2025;206:1092-1096.
    PubMed     Abstract available
    
    
    
30. PRATZ KW
    Advancing the outcomes of AML out of antecedent MPN by targeting mutated IDH1.
    Br J Haematol. 2025;206:1250-1252.
    PubMed     Abstract available
    
    
    
31. FRERICH C, Li P, Raess PW, Dunlap J, et al
    Landscape of somatic mutations and clonal evolution in NUP98-rearranged adult acute myeloid leukaemia.
    Br J Haematol. 2025;206:1097-1102.
    PubMed     Abstract available
    
    
    
32. DE BOTTON S, Recher C, Cortes J, Curti A, et al
    Olutasidenib demonstrates significant clinical activity in mutated IDH1 acute myeloid leukaemia arising from a prior myeloproliferative neoplasm.
    Br J Haematol. 2025;206:1121-1128.
    PubMed     Abstract available
    
    
    March 2025
33. PERUTELLI F, Boccellato E, Montalbano MC, Catania G, et al
    Venetoclax therapy in chronic lymphocytic leukaemia patients relapsed after allogeneic haematopoietic stem cell transplantation.
    Br J Haematol. 2025;206:924-929.
    PubMed     Abstract available
    
    
    
34. SERAFIN A, Ruocco V, Cellini A, Angotzi F, et al
    Management strategies for patients with chronic lymphocytic leukaemia harbouring complex karyotype.
    Br J Haematol. 2025;206:832-841.
    PubMed     Abstract available
    
    
    
35. VALTIS YK, Luskin MR
    Better late than never: Delayed asparaginase during induction for acute lymphoblastic leukaemia in adults.
    Br J Haematol. 2025;206:1016-1017.
    PubMed     Abstract available
    
    
    
36. LAING A, Elmarghany A, Alghaith AA, Gouma A, et al
    Paediatric bone marrow mesenchymal stem cells support acute myeloid leukaemia cell survival and enhance chemoresistance via contact-independent mechanism.
    Br J Haematol. 2025;206:858-863.
    PubMed     Abstract available
    
    
    
37. TINAJERO J, Xu S, Ngo D, Li S, et al
    Delaying pegaspargase during induction in adults with acute lymphoblastic leukaemia is associated with lower risk of high-grade hepatotoxicity without adversely impacting outcomes.
    Br J Haematol. 2025;206:868-875.
    PubMed     Abstract available
    
    
    February 2025
38. ZHAO J, Liu TF, Wu KF, Yang LC, et al
    Clinical and molecular characteristics of paediatric mature B-cell acute lymphocytic leukaemia and non-Hodgkin lymphoma with bone marrow involvement: A joint study between the CCCG leukaemia and lymphoma groups.
    Br J Haematol. 2025 Feb 17. doi: 10.1111/bjh.20011.
    PubMed     Abstract available
    
    
    
39. CHEN Z, Ren A, Li Y, Shu J, et al
    mRNA-laden lipid nanoparticle-enabled humanized CD19 CAR-T-cell engineering for the eradication of leukaemic cells.
    Br J Haematol. 2025;206:628-643.
    PubMed     Abstract available
    
    
    
40. LIN CC, Hsu CL, Yao CY, Wang YH, et al
    HOPX as a tumour-suppressive protein in T-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2025;206:505-516.
    PubMed     Abstract available
    
    
    
41. GANZEL C, Frisch A, Wolach O, Moshe Y, et al
    CPX-351 +/- gemtuzumab ozogamicin as induction therapy for adult patients with newly diagnosed, favourable-intermediate risk, FLT3-ITD negative, AML: A pilot study.
    Br J Haematol. 2025;206:551-555.
    PubMed     Abstract available
    
    
    
42. GURNARI C, Visconte V
    Dissecting the genomic traits and clinical course of secondary myelodysplastic syndrome following aplastic anaemia: A milestone.
    Br J Haematol. 2025;206:790-791.
    PubMed     Abstract available
    
    
    
43. ESTELLER M
    Targeting RNA modifications in leukaemia: Epitranscriptomic drugs are the new kids on the block.
    Br J Haematol. 2025;206:785-787.
    PubMed     Abstract available
    
    
    
44. CHEN X, Gong RZ, Mo LY, Cheng YT, et al
    Hydroxy-wybutosine tRNA modifications as indicators of disease progression and therapeutic targets in leukaemia.
    Br J Haematol. 2025;206:517-530.
    PubMed     Abstract available
    
    
    January 2025
45. SWEET K, Cluzeau T
    Clinical perspectives on post-induction maintenance therapy in patients with acute myeloid leukaemia in remission who are ineligible for allogeneic haematopoietic stem cell transplantation.
    Br J Haematol. 2025;206:61-68.
    PubMed     Abstract available
    
    
    
46. COSTA A, Scalzulli E, Breccia M
    Chronic eosinophilic leukaemia-Not otherwise specified: Clinical features, genomic insight and therapeutic strategies.
    Br J Haematol. 2025;206:44-60.
    PubMed     Abstract available
    
    
    
47. HA TQ, Andresen V, Erikstein BS, Popa M, et al
    Preclinical activity of resazurin in acute myeloid leukaemia.
    Br J Haematol. 2025;206:109-119.
    PubMed     Abstract available
    
    
    
48. JIANG L, Cheng J, Sun J, Zhang Y, et al
    Dynamics of measurable residual disease for risk stratification and guiding allogeneic transplant in acute myeloid leukaemia patients with myelodysplasia-related mutations in first remission.
    Br J Haematol. 2025;206:250-262.
    PubMed     Abstract available
    
    
    
49. VEDI A, Leiter SM, Memon IL, Mahendrayogam A, et al
    Real-world experience of paediatric acute promyelocytic leukaemia in the United Kingdom and Ireland.
    Br J Haematol. 2025;206:204-208.
    PubMed     Abstract available
    
    
    
50. DAVIDS MS, Lin KH, Mohamed AI, Munir T, et al
    Measurable residual disease-driven treatment in first-line chronic lymphocytic leukaemia.
    Br J Haematol. 2025;206:33-43.
    PubMed     Abstract available
    
    
    
51. TRKA J, Fronkova E
    Minimal residual disease detection for acute lymphoblastic leukaemia in peripheral blood-Are we there yet?
    Br J Haematol. 2025;206:397-398.
    PubMed     Abstract available
    
    
    
52. HUANG Q, Jiang X, Wang B, Wu Z, et al
    Gallic acid enhances GVL effects of T cells without exacerbating GVHD after haematopoietic stem cell transplantation.
    Br J Haematol. 2025;206:120-132.
    PubMed     Abstract available
    
    
    
53. THERON A, Alonso-Saladrigues A, Dapena JL, Lopez-Duarte M, et al
    Secondary haematological dysplasia after CAR-T-cell therapy for acute lymphoblastic leukaemia in children.
    Br J Haematol. 2025;206:186-194.
    PubMed     Abstract available
    
    
    
54. COUSSON S, Calvo C, Goldwirt L, Simonin M, et al
    Monocentric experience of venetoclax-based regimen in paediatric refractory and relapsed AML/MDS.
    Br J Haematol. 2025;206:209-214.
    PubMed     Abstract available
    
    
    December 2024
55. FROST EL, Chonat S, Williams KM, Aumann W, et al
    Fatal thrombotic microangiopathy during induction for acute myeloid leukemia: A case report and review of vascular complications in germline GATA2 haploinsufficiency.
    Br J Haematol. 2024 Dec 8. doi: 10.1111/bjh.19935.
    PubMed    
    
    
    
56. HUGUET F, Guerci-Bresler A, Roth-Guepin G, Cayssials E, et al
    Clinical outcomes in patients in any phase of CML treated with ponatinib in France-Data from the TOPASE observational study.
    Br J Haematol. 2024;205:2295-2304.
    PubMed     Abstract available
    
    
    
57. MORIGUCHI M, Nakamae H, Nishimoto M, Sugita J, et al
    Comparison of HLA-haploidentical donors with post-transplant cyclophosphamide versus HLA-matched unrelated donors in peripheral blood stem cell transplantation for acute myeloid leukaemia.
    Br J Haematol. 2024;205:2376-2386.
    PubMed     Abstract available
    
    
    
58. KONDO T
    A new face in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia.
    Br J Haematol. 2024;205:2131-2133.
    PubMed     Abstract available
    
    
    
59. PULA AE, Robak T
    The discovery of the RCC1::IRF4 Fusion in CLL patients with t(1;6)(p35.3;p25.2) chromosomal translocation.
    Br J Haematol. 2024;205:2125-2127.
    PubMed     Abstract available
    
    
    
60. BOUSSI L, Biswas J, Abdel-Wahab O, Stein E, et al
    Therapeutic strategies targeting aberrant RNA splicing in myeloid malignancies.
    Br J Haematol. 2024;205:2153-2162.
    PubMed     Abstract available
    
    
    
61. JAYNE S, Lopez C, Put N, Nagel I, et al
    The chromosomal translocation t(1;6)(p35.3;p25.2), recurrent in chronic lymphocytic leukaemia, leads to RCC1::IRF4 fusion.
    Br J Haematol. 2024;205:2321-2326.
    PubMed     Abstract available
    
    
    
62. TERUEL-MONTOYA R, Rivera J, Lozano ML
    The importance of genetic variant cleaners: From patient to wet lab and back to clinical practice.
    Br J Haematol. 2024;205:2122-2124.
    PubMed     Abstract available
    
    
    
63. KAMIYA LJ, Barozzi S, Isidori F, Ganiewich D, et al
    Two novel families with RUNX1 variants indicate glycine 168 as a new mutational hotspot: Implications for FPD/AML diagnosis.
    Br J Haematol. 2024;205:2315-2320.
    PubMed     Abstract available
    
    
    
64. LIU W, Wang C, Ouyang W, Hao J, et al
    Efficacy and safety of olverembatinib in adult BCR::ABL1-positive ALL with T315I mutation or relapsed/refractory disease.
    Br J Haematol. 2024;205:2228-2233.
    PubMed     Abstract available
    
    
    
65. ASHOURI K, Hom B, Ginosyan AA, Rahimi Y, et al
    Philadelphia-like B-cell acute lymphoblastic leukaemia: Disease features and outcomes in the era of immunotherapy.
    Br J Haematol. 2024;205:2234-2247.
    PubMed     Abstract available
    
    
    November 2024
66. LV M, Yan CH, Ma R, He Y, et al
    Mega-dose decitabine conditioning and prophylactic donor lymphocyte infusion for patients with relapsed/refractory AML with active disease at the time of allogeneic haematopoietic cell transplantation: A multicenter prospective phase II study.
    Br J Haematol. 2024;205:1910-1920.
    PubMed     Abstract available
    
    
    
67. BOULIGNY IM, DiNardo CD
    Oral decitabine-cedazuridine in acute myeloid leukaemia.
    Br J Haematol. 2024;205:1674-1676.
    PubMed     Abstract available
    
    
    
68. GEISSLER K, Koristek Z, Del Castillo TB, Novak J, et al
    Oral decitabine/cedazuridine versus intravenous decitabine for acute myeloid leukaemia: A randomised, crossover, registration, pharmacokinetics study.
    Br J Haematol. 2024;205:1734-1745.
    PubMed     Abstract available
    
    
    
69. PHILIP C, Selvarajan S, Nayak L, Jain H, et al
    Impact of the COVID-19 pandemic on treatment of patients with acute myeloid leukaemia in India.
    Br J Haematol. 2024;205:2058-2062.
    PubMed     Abstract available
    
    
    
70. YANADA M
    Leucocytosis during all-trans retinoic acid and arsenic trioxide treatment in acute promyelocytic leukaemia.
    Br J Haematol. 2024;205:1672-1673.
    PubMed     Abstract available
    
    
    
71. MAILLET F, Galimard JE, Borie R, Lainey E, et al
    Haematological features of telomere biology disorders diagnosed in adulthood: A French nationwide study of 127 patients.
    Br J Haematol. 2024;205:1835-1847.
    PubMed     Abstract available
    
    
    
72. ARIFFIN H
    Incorrigible inflammation.
    Br J Haematol. 2024;205:1679-1680.
    PubMed     Abstract available
    
    
    
73. CICCONI L, Bisegna M, Gurnari C, Fanciullo D, et al
    Leucocytosis during induction therapy with all-trans-retinoic acid and arsenic trioxide in acute promyelocytic leukaemia predicts differentiation syndrome and treatment-related complications.
    Br J Haematol. 2024;205:1727-1733.
    PubMed     Abstract available
    
    
    
74. SPECTOR LG, de Smith AJ
    Backtracking childhood leukaemia to birth: A battle of addition.
    Br J Haematol. 2024;205:1670-1671.
    PubMed     Abstract available
    
    
    
75. YANG YT, Yao CY, Kao CJ, Chiu PJ, et al
    Clinical relevance of NFYA splice variants in patients with acute myeloid leukaemia undergoing intensive chemotherapy.
    Br J Haematol. 2024;205:1751-1764.
    PubMed     Abstract available
    
    
    
76. XU N, Dao FT, Shi ZY, Sun K, et al
    WT1 together with RUNX1::RUNX1T1 targets DUSP6 to dampen ERK activity in acute myeloid leukaemia.
    Br J Haematol. 2024;205:1848-1859.
    PubMed     Abstract available
    
    
    
77. ZHU Q, Nambiar R, Schultz E, Gao X, et al
    Genome-wide study identifies novel genes associated with bone toxicities in children with acute lymphoblastic leukaemia.
    Br J Haematol. 2024;205:1889-1898.
    PubMed     Abstract available
    
    
    
78. BARDINI M, Fazio G, Abascal LC, Meyer C, et al
    Prenatal origin of NUTM1 gene rearrangement in infant B-cell precursor acute lymphoblastic leukaemia.
    Br J Haematol. 2024;205:1883-1888.
    PubMed     Abstract available
    
    
    
79. WEINBERGEROVA B, Mayer J, Kabut T, Sperr WR, et al
    Fungal infection frequency in newly diagnosed acute myeloid leukaemia patients treated with venetoclax plus azacitidine with or without antifungal prophylaxis.
    Br J Haematol. 2024;205:1746-1750.
    PubMed     Abstract available
    
    
    October 2024
80. YOSHIMITSU M, Tanaka T, Nakano N, Kato K, et al
    Comparative outcomes of various transplantation platforms, highlighting haploidentical transplants with post-transplantation cyclophosphamide for adult T-cell leukaemia/lymphoma.
    Br J Haematol. 2024 Oct 19. doi: 10.1111/bjh.19835.
    PubMed     Abstract available
    
    
    
81. NAKAMURA M, Chonabayashi K, Narita M, Matsumura Y, et al
    Modelling and drug targeting of a myeloid neoplasm with atypical 3q26/MECOM rearrangement using patient-specific iPSCs.
    Br J Haematol. 2024;205:1430-1443.
    PubMed     Abstract available
    
    
    
82. GHOSH N, Manzoor BS, Fakhri B, Emechebe N, et al
    Real-world comparative effectiveness of venetoclax-obinutuzumab versus Bruton tyrosine kinase inhibitors for frontline chronic lymphocytic leukaemia.
    Br J Haematol. 2024;205:1395-1403.
    PubMed     Abstract available
    
    
    
83. GAO MY, Georgiou A, Lin VS, Jahja M, et al
    Potential impact of NOTCH1 activation on venetoclax sensitivity in chronic lymphocytic Leukaemia: In vitro insights and clinical implications.
    Br J Haematol. 2024;205:1389-1394.
    PubMed     Abstract available
    
    
    
84. MEHTA P, Campbell V, Maddox J, Floisand Y, et al
    CREST-UK: Real-world effectiveness, safety and outpatient delivery of CPX-351 for first-line treatment of newly diagnosed therapy-related AML and AML with myelodysplasia-related changes in the UK.
    Br J Haematol. 2024;205:1326-1336.
    PubMed     Abstract available
    
    
    
85. ANASTASOPOULOU S, Swann G, Andres-Jensen L, Attarbaschi A, et al
    Severe steroid-related neuropsychiatric symptoms during paediatric acute lymphoblastic leukaemia therapy-An observational Ponte di Legno Toxicity Working Group Study.
    Br J Haematol. 2024;205:1450-1459.
    PubMed     Abstract available
    
    
    September 2024
86. NARESH KN
    Understanding splenic B-cell lymphoma/leukaemia with prominent nucleoli: Diagnosis, underpinnings for disease classification and future directions.
    Br J Haematol. 2024 Sep 10. doi: 10.1111/bjh.19754.
    PubMed     Abstract available
    
    
    
87. HEI Z, Yang S, Ouyang G, Hanna J, et al
    Targeting the redox vulnerability of acute myeloid leukaemia cells with a combination of auranofin and vitamin C.
    Br J Haematol. 2024;205:1017-1030.
    PubMed     Abstract available
    
    
    
88. LEBLANC FR, Breese EH, Burns KC, Chang EK, et al
    Clinical outcomes of hypomethylating agents and venetoclax in newly diagnosed unfit and relapsed/refractory paediatric, adolescent and young adult acute myeloid leukaemia patients.
    Br J Haematol. 2024;205:1055-1066.
    PubMed     Abstract available
    
    
    
89. HUANG C, Jia Y, Yang J, Cai Y, et al
    Azacitidine combined with interferon-alpha for pre-emptive treatment of AML/MDS after allogeneic peripheral blood stem cell transplantation: A prospective phase II study.
    Br J Haematol. 2024;205:1067-1076.
    PubMed     Abstract available
    
    
    
90. GOVER-PROAKTOR A, Leshem-Lev D, Winograd-Katz S, Partouche S, et al
    Dasatinib induces endothelial dysfunction leading to impaired recovery from ischaemia.
    Br J Haematol. 2024;205:1011-1016.
    PubMed     Abstract available
    
    
    
91. KUGLER E, Cohen I, Amitai I, Ram R, et al
    Gilteritinib with or without venetoclax for relapsed/refractory FLT3-mutated acute myeloid leukaemia.
    Br J Haematol. 2024;205:932-941.
    PubMed     Abstract available
    
    
    
92. KUHN MWM, Ganser A
    The Menin story in acute myeloid leukaemia-The road to success.
    Br J Haematol. 2024;205:812-814.
    PubMed     Abstract available
    
    
    
93. ZHAO S, Wang J, Lou Y, Huang X, et al
    Clinical characteristics of acute myeloid leukaemia patients with a large number of azurophilic granules: A single-centre retrospective study.
    Br J Haematol. 2024;205:924-931.
    PubMed     Abstract available
    
    
    
94. ROBERTSON HF, Milojkovic D, Butt N, Byrne J, et al
    Expectations and outcomes of varying treatment strategies for CML presenting during pregnancy.
    Br J Haematol. 2024;205:947-955.
    PubMed     Abstract available
    
    
    
95. MARCHAND T, Pastoret C, Damaj G, Lebouvier A, et al
    Efficacy of ruxolitinib in the treatment of relapsed/refractory large granular lymphocytic leukaemia.
    Br J Haematol. 2024;205:915-923.
    PubMed     Abstract available
    
    
    August 2024
96. GLANZMANN J, Kalberer C, Bonadies N, Colucci G, et al
    Plasma cells with Auer-rod-like inclusions in a patient with MGUS and acute myeloid leukaemia with NPM1 mutation.
    Br J Haematol. 2024;205:401-402.
    PubMed    
    
    
    
97. YANG F, Ren Q, Zu Y, Gui R, et al
    Multiple small-dose infusions of G-CSF-mobilized haploidentical lymphocytes after autologous haematopoietic stem cell transplantation for acute myeloid leukaemia.
    Br J Haematol. 2024;205:645-652.
    PubMed     Abstract available
    
    
    
98. TRINQUAND A, Betts DR, Rooney S, Storey L, et al
    MRD-risk stratification mitigates TLX3 prognostic impact in paediatric T-cell acute lymphoblastic leukaemia: A national cohort analysis.
    Br J Haematol. 2024;205:729-732.
    PubMed    
    
    
    
99. CHEN C, Li J, Chen Y, Gao Q, et al
    The correlation of asparaginase enzyme activity levels after PEG-asparaginase administration with clinical characteristics and adverse effects in Chinese paediatric patients with acute lymphoblastic leukaemia.
    Br J Haematol. 2024;205:624-633.
    PubMed     Abstract available
    
    
    
100. ZHU W, Ding Y, Huang W, Guo N, et al
     Synergistic effects of the KDM4C inhibitor SD70 and the menin inhibitor MI-503 against MLL::AF9-driven acute myeloid leukaemia.
     Br J Haematol. 2024;205:568-579.
     PubMed     Abstract available
     
     
     
101. GRADY E, Biswas S, Dias T, McCarthy P, et al
     A novel TCF3::PIK3R1 fusion linked to decreased PI3K-AKT signalling activity in paediatric B-acute lymphoblastic leukaemia.
     Br J Haematol. 2024;205:738-741.
     PubMed    
     
     
     
102. OTHMAN T, Koller P, Pourhassan H, Agrawal V, et al
     Tyrosine kinase inhibitor maintenance following chimeric antigen receptor T-cell therapy in Philadelphia chromosome-positive acute lymphoblastic leukaemia.
     Br J Haematol. 2024;205:711-715.
     PubMed    
     
     
     
103. WANG S, Liu Y, Zhao X, Wang X, et al
     RUNX1::ETO and CBFbeta::MYH11 converge on aberrant activation of BCAT1 to confer a therapeutic vulnerability in core-binding factor-acute myeloid leukaemia.
     Br J Haematol. 2024;205:552-567.
     PubMed     Abstract available
     
     
     
104. TANG FF, Duan WB, Liu XH, Lu SY, et al
     A complete oral regimen for induction therapy of patients with high-risk APL: An oral etoposide instead of intravenous infusion for cytoreductive chemotherapy.
     Br J Haematol. 2024;205:510-516.
     PubMed     Abstract available
     
     
     
105. NGUYEN-KHAC F, Baron M, Guieze R, Feugier P, et al
     Prognostic impact of genetic abnormalities in 536 first-line chronic lymphocytic leukaemia patients without 17p deletion treated with chemoimmunotherapy in two prospective trials: Focus on IGHV-mutated subgroups (a FILO study).
     Br J Haematol. 2024;205:495-502.
     PubMed     Abstract available
     
     
     
106. XU X, Huang Z, Ding C, Deng S, et al
     STAT5 phosphorylation plus minimal residual disease defines a novel risk classification in adult B-cell acute lymphoblastic leukaemia.
     Br J Haematol. 2024;205:517-528.
     PubMed     Abstract available
     
     
     
107. BOTTEN GA, Zhang Y, Fuda F, Koduru P, et al
     T/myeloid mixed phenotype acute leukaemia harbouring TLX3::BCL11B with TLX3 activation.
     Br J Haematol. 2024;205:607-612.
     PubMed     Abstract available
     
     
     July 2024
108. ALLEN B, Savoy L, Ryabinin P, Bottomly D, et al
     Upregulation of HOXA3 by isoform-specific Wilms tumour 1 drives chemotherapy resistance in acute myeloid leukaemia.
     Br J Haematol. 2024;205:207-219.
     PubMed     Abstract available
     
     
     
109. RONNACKER J, Urbahn MA, Reicherts C, Kolloch L, et al
     Early blast clearance during sequential conditioning prior to allogeneic stem cell transplantation in patients with acute myeloid leukaemia.
     Br J Haematol. 2024;205:280-290.
     PubMed     Abstract available
     
     
     
110. JIMENEZ-VICENTE C, Charry P, Castano-Diez S, Guijarro F, et al
     Evaluation of European LeukemiaNet 2022 risk classification in patients undergoing allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia: Identification of a very poor prognosis genetic group.
     Br J Haematol. 2024;205:256-267.
     PubMed     Abstract available
     
     
     
111. PICHLER H, Sedlacek P, Meisel R, Beier R, et al
     Haematopoietic stem cell transplantation after reduced intensity conditioning in children and adolescents with chronic myeloid leukaemia: A prospective multicentre trial of the I-BFM Study Group.
     Br J Haematol. 2024;205:268-279.
     PubMed     Abstract available
     
     
     
112. TAURINO G, Dander E, Chiu M, Pozzi G, et al
     Asparagine transport through SLC1A5/ASCT2 and SLC38A5/SNAT5 is essential for BCP-ALL cell survival and a potential therapeutic target.
     Br J Haematol. 2024;205:175-188.
     PubMed     Abstract available
     
     
     
113. WANG HY, Louis HMS, Costello CL, Murray SS, et al
     A CD10-negative adult B-lymphoblastic leukaemia with amplification of KMT2A without rearrangement: A case report and review of the English literature.
     Br J Haematol. 2024;205:364-367.
     PubMed    
     
     
     
114. DOURTHE ME, Yakouben K, David A, Thouvenin S, et al
     Success of donor-derived CAR-T cells after failure of autologous CD19 CAR-T cells (tisagenlecleucel) in B-cell acute lymphoblastic leukaemia.
     Br J Haematol. 2024;205:373-377.
     PubMed    
     
     
     
115. JEN WY, Kantarjian H, Kadia TM, DiNardo CD, et al
     Combination therapy with novel agents for acute myeloid leukaemia: Insights into treatment of a heterogenous disease.
     Br J Haematol. 2024;205:30-47.
     PubMed     Abstract available
     
     
     
116. SERAFIN A, Cellini A, Cavarretta CA, Ruocco V, et al
     Exploring the prognostic role of complex karyotype in chronic lymphocytic leukaemia patients treated with venetoclax-based regimens.
     Br J Haematol. 2024;205:189-193.
     PubMed     Abstract available
     
     
     
117. ZHANG X, Zhong Y, Liu L, Suo S, et al
     MN1::ETV6-positive de novo T-cell acute lymphoblastic leukaemia is sensitive to venetoclax: A case report.
     Br J Haematol. 2024;205:352-355.
     PubMed    
     
     
     
118. IYENGAR L, Fong CY, Prakash S, Chong AH, et al
     Cutaneous involvement in chronic lymphocytic leukaemia.
     Br J Haematol. 2024;205:11.
     PubMed    
     
     
     
119. POURHASSAN H, Zhang J, Tinajero J, Pullarkat V, et al
     Therapy-related acute lymphoblastic leukaemia in women with antecedent breast cancer.
     Br J Haematol. 2024;205:158-165.
     PubMed     Abstract available
     
     
     June 2024
120. XU J, Peng J, Sun S, Wang D, et al
     Preclinical testing of CT1113, a novel USP28 inhibitor, for the treatment of T-cell acute lymphoblastic leukaemia.
     Br J Haematol. 2024;204:2301-2318.
     PubMed     Abstract available
     
     
     
121. DELGADO J
     InsT-ALLing CD7 chimeric antigen receptors before transplantation.
     Br J Haematol. 2024;204:2155-2156.
     PubMed     Abstract available
     
     
     
122. ENJETI AK, Fogler WE, Smith TAG, Lincz LF, et al
     Combining 5-azacitidine with the E-selectin antagonist uproleselan is an effective strategy to augment responses in myelodysplasia and acute myeloid leukaemia.
     Br J Haematol. 2024;204:2264-2274.
     PubMed     Abstract available
     
     
     
123. ORTIZ ROJAS CA, Pereira-Martins DA, Bellido More CC, Sternadt D, et al
     A 4-gene prognostic index for enhancing acute myeloid leukaemia survival prediction.
     Br J Haematol. 2024;204:2287-2300.
     PubMed     Abstract available
     
     
     
124. LIU H, Wu K, Hu W, Chen X, et al
     Immunophenotypic clustering in paediatric acute myeloid leukaemia.
     Br J Haematol. 2024;204:2275-2286.
     PubMed     Abstract available
     
     
     
125. MAO S, Lin Y, Qin X, Miao Y, et al
     Droplet digital PCR: An effective method for monitoring and prognostic evaluation of minimal residual disease in JMML.
     Br J Haematol. 2024;204:2332-2341.
     PubMed     Abstract available
     
     
     
126. JEN WY, Sasaki K, Loghavi S, Wang SA, et al
     Characteristics and outcomes of acute myeloid leukaemia patients with baseline CD7 expression.
     Br J Haematol. 2024;204:2259-2263.
     PubMed     Abstract available
     
     
     
127. KINSELLA FAM, Maroto MAL, Loke J, Craddock C, et al
     Strategies to reduce relapse risk in patients undergoing allogeneic stem cell transplantation for acute myeloid leukaemia.
     Br J Haematol. 2024;204:2173-2183.
     PubMed     Abstract available
     
     
     
128. ROLLIG C, Schliemann C, Ruhnke L, Fransecky L, et al
     Gemtuzumab ozogamicin plus midostaurin in combination with standard '7 + 3' induction therapy in newly diagnosed AML: Results from the SAL-MODULE phase I study.
     Br J Haematol. 2024;204:2254-2258.
     PubMed     Abstract available
     
     
     
129. ONIDA F, Gras L, Ge J, Koster L, et al
     Mismatched related donor allogeneic haematopoietic cell transplantation compared to other donor types for Ph+ chronic myeloid leukaemia: A retrospective analysis from the Chronic Malignancies Working Party of the EBMT.
     Br J Haematol. 2024;204:2365-2377.
     PubMed     Abstract available
     
     
     
130. HARROP S, Nguyen PC, Robinson S, Nguyen T, et al
     Immunophenotypic characterisation of acute myeloid leukaemia with UBTF tandem duplications.
     Br J Haematol. 2024;204:2492-2495.
     PubMed    
     
     
     
131. BARNBROCK A, Moricke A, Barbaric D, Jones N, et al
     Pneumocystis jirovecii pneumonia in paediatric acute lymphoblastic leukaemia: A report from the multi-international clinical trial AIEOP-BFM ALL 2009.
     Br J Haematol. 2024;204:2319-2323.
     PubMed     Abstract available
     
     
     
132. DONG Q, Wang Y, Xiu Y, Wu X, et al
     Unveiling myeloid transformation: T-LGLL with eosinophilia masking myeloid-associated STAT5B mutation culminating in AML.
     Br J Haematol. 2024;204:2487-2491.
     PubMed    
     
     
     
133. BAUCH T, Hempel G
     Proof of concept of physiologically based pharmacokinetic modelling in paediatric acute lymphoblastic leukaemia.
     Br J Haematol. 2024;204:2324-2331.
     PubMed     Abstract available
     
     
     May 2024
134. RUPAKUMAR T, Sankar A, Vijayasekharan K, Varikkattu Rajendran P, et al
     Older age, CNS leukaemic involvement and induction tumour lysis increases the risk of methotrexate (MTX)-induced neurotoxicity in childhood acute lymphoblastic leukaemia/lymphoma: Experience from a tertiary care centre in South India.
     Br J Haematol. 2024 May 26. doi: 10.1111/bjh.19559.
     PubMed     Abstract available
     
     
     
135. BALDUZZI A
     The CAR T-cell race: The rules of the game.
     Br J Haematol. 2024;204:1579-1581.
     PubMed     Abstract available
     
     
     
136. ZHANG X, Tao C, Long F
     Haematoidin in chronic myelomonocytic leukaemia during irregular treatment with hydroxycarbamide.
     Br J Haematol. 2024;204:1569-1570.
     PubMed    
     
     
     
137. MISHRA AK, Burridge S, Espuelas MO, O'Reilly M, et al
     Practice guideline: Preparation for CAR T-cell therapy in children and young adults with B-acute lymphoblastic leukaemia.
     Br J Haematol. 2024;204:1687-1696.
     PubMed     Abstract available
     
     
     
138. KRIEGER E, Qayyum R, Toor A
     Increased donor inhibitory KIR are associated with reduced GVHD and improved survival following HLA-matched unrelated donor HCT in paediatric acute leukaemia.
     Br J Haematol. 2024;204:1935-1943.
     PubMed     Abstract available
     
     
     
139. LEBECQUE B, Besombes J, Dannus LT, De Antonio M, et al
     Faster clinical decisions in B-cell acute lymphoblastic leukaemia: A single flow cytometric 12-colour tube improves diagnosis and minimal residual disease follow-up.
     Br J Haematol. 2024;204:1872-1881.
     PubMed     Abstract available
     
     
     
140. JO T, Ueda T, Akahoshi Y, Kondo T, et al
     First complete remission favours haploidentical haematopoietic stem cell transplantation with post-transplant cyclophosphamide over cord blood transplantation in acute lymphoblastic leukaemia.
     Br J Haematol. 2024;204:1913-1919.
     PubMed     Abstract available
     
     
     
141. BOUKOUACI W, Rivera-Franco MM, Volt F, Lajnef M, et al
     HLA peptide-binding pocket diversity modulates immunological complications after cord blood transplant in acute leukaemia.
     Br J Haematol. 2024;204:1920-1934.
     PubMed     Abstract available
     
     
     
142. BRILLEMBOURG H, Martinez-Cibrian N, Bachiller M, Alserawan L, et al
     The role of chimeric antigen receptor T cells targeting more than one antigen in the treatment of B-cell malignancies.
     Br J Haematol. 2024;204:1649-1659.
     PubMed     Abstract available
     
     
     
143. LOH Z, Ashby M, Van Veldhuizen E, Li W, et al
     Arsenic-induced neurotoxicity in patients with acute promyelocytic leukaemia.
     Br J Haematol. 2024;204:1732-1739.
     PubMed     Abstract available
     
     
     April 2024
144. HUO W, Gao L, Song K, Huang J, et al
     Allogeneic haematopoietic stem cell transplantation for adult T-lymphoblastic lymphoma: A real-world multicentre analysis in China.
     Br J Haematol. 2024 Apr 25. doi: 10.1111/bjh.19481.
     PubMed     Abstract available
     
     
     
145. CAO XY, Zhang JP, Lu Y, Zhao YL, et al
     A safety and efficacy study of allogeneic haematopoietic stem cell transplantation for refractory and relapsed T-cell acute lymphoblastic leukaemia/lymphoblastic lymphoma patients who achieved complete remission after autologous CD7 chimeric antigen r
     Br J Haematol. 2024 Apr 13. doi: 10.1111/bjh.19445.
     PubMed     Abstract available
     
     
     
146. LIU HC, Huang YJ, Jaing TH, Wu KH, et al
     Refining risk stratification in paediatric B-acute lymphoblastic leukaemia: Combining IKZF1(plus) and Day 15 MRD positivity.
     Br J Haematol. 2024;204:1344-1353.
     PubMed     Abstract available
     
     
     
147. BOMMANNAN K, Arumugam JR, Radhakrishnan V, Sundersingh S, et al
     Relevance of CD20 antigen expression among paediatric patients with B-lineage acute lymphoblastic leukaemia.
     Br J Haematol. 2024;204:1367-1374.
     PubMed     Abstract available
     
     
     
148. CHEN X, Li J, Yu L, Hu W, et al
     High-dose methotrexate pharmacokinetics and its impact on prognosis of paediatric acute lymphoblastic leukaemia patients: A population pharmacokinetic study.
     Br J Haematol. 2024;204:1354-1366.
     PubMed     Abstract available
     
     
     
149. MOSQUERA ORGUEIRA A, Perez Encinas MM, Diaz Varela N, Wang YH, et al
     Validation of the Artificial Intelligence Prognostic Scoring System for Myelodysplastic Syndromes in chronic myelomonocytic leukaemia: A novel approach for improved risk stratification.
     Br J Haematol. 2024;204:1529-1535.
     PubMed     Abstract available
     
     
     
150. STENTOFT J
     The Mozart effect in chronic myeloid leukaemia.
     Br J Haematol. 2024;204:1139-1140.
     PubMed     Abstract available
     
     
     
151. PATEL SA
     The heart of VIALE-A: Cardiac complications of hypomethylating agents and venetoclax in acute myeloid leukaemia.
     Br J Haematol. 2024;204:1137-1138.
     PubMed     Abstract available
     
     
     
152. ZHANG T, Zhang Y, Zhou M, Zhang Z, et al
     Risk factors and survival analysis of human leukocyte antigen loss in relapsed acute myeloid leukaemia/myelodysplastic syndrome patients after allogeneic haematopoietic stem cell transplantation.
     Br J Haematol. 2024;204:1402-1413.
     PubMed     Abstract available
     
     
     
153. ALCAZER V, Morisset S, Rea D, Legros L, et al
     Kinetics of molecular recurrence after tyrosine kinase inhibitor cessation in chronic phase chronic myelogenous leukaemia patients.
     Br J Haematol. 2024;204:1536-1539.
     PubMed    
     
     
     
154. JOHNSON IM, Karrar O, Rana M, Iftikhar M, et al
     Cardiac events in newly diagnosed acute myeloid leukaemia during treatment with venetoclax + hypomethylating agents.
     Br J Haematol. 2024;204:1232-1237.
     PubMed     Abstract available
     
     
     
155. NACHMIAS B, Aumann S, Haran A, Schimmer AD, et al
     Venetoclax resistance in acute myeloid leukaemia-Clinical and biological insights.
     Br J Haematol. 2024;204:1146-1158.
     PubMed     Abstract available
     
     
     
156. ZUCENKA A, Griskevicius L
     Gilteritinib in combination with venetoclax, low-dose cytarabine and actinomycin D for relapsed or refractory FLT3-mutated acute myeloid leukaemia.
     Br J Haematol. 2024;204:1227-1231.
     PubMed     Abstract available
     
     
     
157. SUWANNAYING K, Ong AA, Dhaduk R, Pei D, et al
     Quantitative computed tomography analysis of body composition changes in paediatric patients with acute lymphoblastic leukaemia.
     Br J Haematol. 2024;204:1335-1343.
     PubMed     Abstract available
     
     
     
158. FIEDLER W
     Therapy with hypomethlyating agents/venetoclax in patients with newly diagnosed acute myeloid leukaemia requiring admission to the intensive care unit: Possible reduction in side effects with preserved efficacy.
     Br J Haematol. 2024;204:1135-1136.
     PubMed     Abstract available
     
     
     
159. LIANG P, Xie Y, Liu Z, Wang D, et al
     Venetoclax and hypomethylating agents in critically ill patients with newly diagnosed acute myeloid leukaemia.
     Br J Haematol. 2024;204:1219-1226.
     PubMed     Abstract available
     
     
     
160. ROY MOULIK N, Keerthivasagam S, Pandey A, Agiwale J, et al
     Treatment and follow-up of children with chronic myeloid leukaemia in chronic phase (CML-CP) in the tyrosine kinase inhibitor (TKI) era-Two decades of experience from the Tata Memorial Hospital paediatric CML (pCML) cohort.
     Br J Haematol. 2024;204:1249-1261.
     PubMed     Abstract available
     
     
     
161. MADERO-MARROQUIN R, DuVall AS, Saygin C, Wang P, et al
     Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and IDH inhibitors.
     Br J Haematol. 2024;204:1238-1242.
     PubMed     Abstract available
     
     
     
162. LIGIA S, Passucci M, Assanto GM, D'Elia GM, et al
     Early clearance of hairy cell leukaemia in the bone marrow after first-line treatment with cladribine predicts a favourable outcome.
     Br J Haematol. 2024;204:1288-1292.
     PubMed     Abstract available
     
     
     March 2024
163. LARIBI K, Poulain S, Willems L, Merabet F, et al
     Long-term results of Waldenstrom macroglobulinaemia treatment by bendamustine and rituximab: A study on behalf of the French Innovative Leukemia Organization (FILO).
     Br J Haematol. 2024 Mar 19. doi: 10.1111/bjh.19409.
     PubMed     Abstract available
     
     
     
164. NG HL, Robinson ME, May PC, Innes AJ, et al
     Promoter-centred chromatin interactions associated with EVI1 expression in EVI1+3q- myeloid leukaemia cells.
     Br J Haematol. 2024;204:945-958.
     PubMed     Abstract available
     
     
     
165. SUN H, Zhu Y, Li J, Zhao L, et al
     CSF3R P733T is a deleterious germline variant in acute leukaemia showing gain-of-function-like T618I mutation.
     Br J Haematol. 2024;204:e31-e33.
     PubMed    
     
     
     
166. SHIMONY S, Chen EC
     Tri-ing to decipher trisomy AML.
     Br J Haematol. 2024;204:751-752.
     PubMed     Abstract available
     
     
     
167. TAN JY, Yeo YH, Tan MC, Chavez JC, et al
     Mortality trends of chronic lymphocytic leukaemia in the United States with the emergence of targeted therapy.
     Br J Haematol. 2024;204:1114-1117.
     PubMed    
     
     
     
168. ZHAO HG
     Should oligomonocytic CMML be classified as an independent disease entity?
     Br J Haematol. 2024;204:749-750.
     PubMed     Abstract available
     
     
     
169. LAM SSY, Tsui SP, Fung CY, Saw NY, et al
     Distinct karyotypic and mutational landscape in trisomy AML.
     Br J Haematol. 2024;204:939-944.
     PubMed     Abstract available
     
     
     
170. COPLAND M, Ariti C, Thomas IF, Upton L, et al
     A randomised evaluation of low-dose cytosine arabinoside plus lenalidomide versus single-agent low-dose cytosine arabinoside in older patients with acute myeloid leukaemia: Results from the LI-1 trial.
     Br J Haematol. 2024;204:871-876.
     PubMed     Abstract available
     
     
     
171. CASTANO-DIEZ S, Pomares H, Esteban D, Guijarro F, et al
     Characteristics and long-term outcome in a large series of chronic myelomonocytic leukaemia patients including 104 formerly referred to as oligomonocytic.
     Br J Haematol. 2024;204:892-897.
     PubMed     Abstract available
     
     
     
172. LU Q, Qu W, Wen Y, Ke P, et al
     Single-cell RNA-seq reveals the links between the metabolic heterogeneity and cell identity in NBM and AML.
     Br J Haematol. 2024;204:1100-1104.
     PubMed    
     
     
     
173. RAVANDI F, Dohner H, Wei AH, Montesinos P, et al
     Survival outcomes in patients with acute myeloid leukaemia who received subsequent therapy for relapse in QUAZAR AML-001.
     Br J Haematol. 2024;204:877-886.
     PubMed     Abstract available
     
     
     
174. MONTALBAN-BRAVO G, Jabbour E, Borthakur G, Kadia T, et al
     Phase 1/2 study of CPX-351 for patients with Int-2 or high risk International Prognostic Scoring System myelodysplastic syndromes and chronic myelomonocytic leukaemia after failure to hypomethylating agents.
     Br J Haematol. 2024;204:898-909.
     PubMed     Abstract available
     
     
     
175. CHEN N, Pan J, Zhou Y, Mao L, et al
     Gilteritinib-based combination therapy in adult relapsed/refractory FLT3-mutated acute myeloid leukaemia.
     Br J Haematol. 2024;204:861-870.
     PubMed     Abstract available
     
     
     February 2024
176. COSTA A, Breccia M
     How to improve treatment-free remission eligibility in chronic myeloid leukaemia?
     Br J Haematol. 2024;204:434-448.
     PubMed     Abstract available
     
     
     
177. PARDANANI A, Reichard K, Tefferi A
     Advanced systemic mastocytosis-Revised classification, new drugs and how we treat.
     Br J Haematol. 2024;204:402-414.
     PubMed     Abstract available
     
     
     
178. FUJI S, Yuda S, Tada Y, Kano M, et al
     A treatment strategy to mitigate the adverse effect of pretransplant mogamulizumab on post-transplant clinical outcome in patients with aggressive ATL.
     Br J Haematol. 2024;204:e25-e27.
     PubMed    
     
     
     
179. WANG Z, Fan Z, Wu Z, Xuan L, et al
     PASS-ALL study of paediatric-inspired versus adult chemotherapy regimens on survival of high-risk Philadelphia-negative B-cell acute lymphoblastic leukaemia with allogeneic haematopoietic stem cell transplantation.
     Br J Haematol. 2024;204:628-637.
     PubMed     Abstract available
     
     
     
180. KUMAR J, Ewalt MD, Zhang Y, Yao J, et al
     Novel identification of t(14;18)(q32;q21)/IGH::MALT1 in chronic lymphocytic leukaemia.
     Br J Haematol. 2024;204:561-565.
     PubMed     Abstract available
     
     
     
181. NYQUIST OE, Dalgaard J, Spetalen S, Torkildsen S, et al
     Pathogenic DDX41 variants, possible response predictors to low-dose melphalan in hypo- and normocellular MDS and AML.
     Br J Haematol. 2024;204:724-729.
     PubMed    
     
     
     
182. NARDOZZA AM, Guarnera L, Travaglini S, Ottone T, et al
     Characterization of a novel IDH2-R159H mutation in acute myeloid leukaemia: Effects on cell metabolism and differentiation.
     Br J Haematol. 2024;204:719-723.
     PubMed    
     
     
     
183. RAMAMOORTHY S, Lebrecht D, Schanze D, Schanze I, et al
     Biallelic inactivation of the NF1 tumour suppressor gene in juvenile myelomonocytic leukaemia: Genetic evidence of driver function and implications for diagnostic workup.
     Br J Haematol. 2024;204:595-605.
     PubMed     Abstract available
     
     
     
184. MARK C, Meshinchi S, Joyce B, Gibson B, et al
     Treatment outcomes of childhood PICALM::MLLT10 acute leukaemias.
     Br J Haematol. 2024;204:576-584.
     PubMed     Abstract available
     
     
     
185. SHEN Y, Freeman JA, Kerridge I, Downe P, et al
     Repeated COVID-19 vaccination to maximum antibody response yields very low mortality and hospitalisation rates in patients with CLL and MBL.
     Br J Haematol. 2024;204:487-491.
     PubMed     Abstract available
     
     
     
186. BAI L, Zhang ZX, Hu GH, Cheng YF, et al
     Long-term follow-up of haploidentical haematopoietic stem cell transplantation in paediatric patients with high-risk acute myeloid leukaemia: Report from a single centre.
     Br J Haematol. 2024;204:585-594.
     PubMed     Abstract available
     
     
     January 2024
187. MIYASHITA N, Onozawa M, Matsukawa T, Mori A, et al
     Novel stratification for newly diagnosed acute myeloid leukaemia treated with venetoclax-based therapy in the real world: Hokkaido Leukemia Net Study.
     Br J Haematol. 2024 Jan 18. doi: 10.1111/bjh.19292.
     PubMed    
     
     
     
188. NAVRKALOVA V, Plevova K, Radova L, Porc J, et al
     Integrative NGS testing reveals clonal dynamics of adverse genomic defects contributing to a natural progression in treatment-naive CLL patients.
     Br J Haematol. 2024;204:240-249.
     PubMed     Abstract available
     
     
     
189. HASSELBALCH HC, Skov V, Kjaer L, Larsen MK, et al
     Proof of concept of triple COMBI therapy to prohibit MPN progression to AML.
     Br J Haematol. 2024;204:16-18.
     PubMed     Abstract available
     
     
     
190. GJERTSEN BT
     How to discover the exceptional venetoclax responders in AML/MDS?
     Br J Haematol. 2024;204:14-15.
     PubMed    
     
     
     
191. GESTRICH CK, De Lancy SJ, Kresak A, Meyerson H, et al
     IGJ and SPATS2L immunohistochemistry sensitively and specifically identify BCR::ABL1+ and BCR::ABL1-like B-acute lymphoblastic leukaemia.
     Br J Haematol. 2024;204:229-239.
     PubMed     Abstract available
     
     
     
192. BARON F, Nagler A, Galimard JE, Sanz J, et al
     Cord blood transplantation for AML: Comparable LFS in patients with de novo versus secondary AML in CR1, an ALWP/EBMT study.
     Br J Haematol. 2024;204:250-259.
     PubMed     Abstract available
     
     
     
193. DE CASTRO FA, Mehdipour P, Chakravarthy A, Ettayebi I, et al
     Ratio of stemness to interferon signalling as a biomarker and therapeutic target of myeloproliferative neoplasm progression to acute myeloid leukaemia.
     Br J Haematol. 2024;204:206-220.
     PubMed     Abstract available
     
     
     
194. NANAA A, He R, Foran JM, Badar T, et al
     Venetoclax plus hypomethylating agents in DDX41-mutated acute myeloid leukaemia and myelodysplastic syndrome: Mayo Clinic series on 12 patients.
     Br J Haematol. 2024;204:171-176.
     PubMed     Abstract available
     
     
     
195. MURPHY EL
     HTLV-1 and blood donation.
     Br J Haematol. 2024;204:29-30.
     PubMed     Abstract available
     
     
     December 2023
196. HOKLAND P, Fernandez II, Freeman SD, Gjertsen BT, et al
     AML in the elderly-A global view.
     Br J Haematol. 2023;203:760-773.
     PubMed    
     
     
     
197. WU JF, Abid H, Szabo A, Abid MB, et al
     Impact of age on efficacy and safety of chimeric antigen receptor-T in B-cell acute lymphoblastic leukaemia-A systematic review and meta-analysis.
     Br J Haematol. 2023;203:e117-e120.
     PubMed    
     
     
     
198. HERRITY E, Pereira MP, Kim DDH
     Acute myeloid leukaemia relapse after allogeneic haematopoietic stem cell transplantation: Mechanistic diversity and therapeutic directions.
     Br J Haematol. 2023;203:722-735.
     PubMed     Abstract available
     
     
     
199. MAHDI D, O'Nions J, Raj K, Baker R, et al
     Managing molecular relapse of acute myeloid leukaemia in early pregnancy: Is a watch and wait approach reasonable?
     Br J Haematol. 2023;203:e114-e116.
     PubMed    
     
     
     
200. QI P, Wang L, Li H, Wu Y, et al
     Venetoclax as a cytoreduction therapy for acute promyelocytic leukaemia: A single-centre experience.
     Br J Haematol. 2023;203:892-895.
     PubMed    
     
     
     
201. PERUSINI MA, Novitzky-Basso I, Atenafu EG, Forrest D, et al
     Final report of TKI discontinuation trial with dasatinib for the second attempt of treatment-free remission after failing the first attempt with imatinib: Treatment-free Remission Accomplished by Dasatinib (TRAD) study.
     Br J Haematol. 2023;203:781-791.
     PubMed     Abstract available
     
     
     
202. CHIRIAC R, Humbert C, Mejri A, Debliquis A, et al
     Charcot-Leyden crystals in acute myeloid leukaemia associated with basophilia.
     Br J Haematol. 2023;203:699-700.
     PubMed    
     
     
     November 2023
203. NG JY, Joshi M, Choi P
     Frequency and outcomes of obinutuzumab-induced thrombocytopenia.
     Br J Haematol. 2023;203:668-672.
     PubMed     Abstract available
     
     
     
204. BORLENGHI E, Roccaro AM, Cattaneo C
     Rethinking the definition of 'less intensive' for venetoclax-combining regimens in acute myeloid leukaemia patients.
     Br J Haematol. 2023;203:504-506.
     PubMed     Abstract available
     
     
     
205. REYNOLDS G, Urbancic KF, Fong CY, Trubiano JA, et al
     Invasive fungal infection following venetoclax and posaconazole co-administration.
     Br J Haematol. 2023;203:593-598.
     PubMed     Abstract available
     
     
     
206. OCADLIKOVA D, Lussana F, Fracchiolla N, Bonifacio M, et al
     Blinatumomab differentially modulates peripheral blood and bone marrow immune cell repertoire: A Campus ALL study.
     Br J Haematol. 2023;203:637-650.
     PubMed     Abstract available
     
     
     
207. BOOTH E, Backx M, Joshi A, Nizami H, et al
     Disseminated invasive aspergillosis in a patient treated with ibrutinib for chronic lymphocytic leukaemia.
     Br J Haematol. 2023;203:499-500.
     PubMed    
     
     
     
208. DONNETTE M, Hamimed M, Ciccolini J, Sicard G, et al
     Cytidine deaminase status as a marker of response to azacytidine treatment in MDS and AML patients.
     Br J Haematol. 2023;203:625-636.
     PubMed     Abstract available
     
     
     
209. MONTALBAN-BRAVO G, Kanagal-Shamanna R, Li Z, Hammond D, et al
     Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemia.
     Br J Haematol. 2023;203:581-592.
     PubMed     Abstract available
     
     
     
210. APOLITO V, Arrigo G, Vasseur L, Olivi M, et al
     Validation of SIE/SIES/GITMO consensus criteria for unfitness to predict early mortality and survival in acute myeloid leukaemia patients treated with hypomethylating agents and venetoclax.
     Br J Haematol. 2023;203:e98-e101.
     PubMed    
     
     
     October 2023
211. MARTINEZ-CIBRIAN N, Ortiz-Maldonado V, Espanol-Rego M, Blazquez A, et al
     The academic point-of-care anti-CD19 chimeric antigen receptor T-cell product varnimcabtagene autoleucel (ARI-0001 cells) shows efficacy and safety in the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma.
     Br J Haematol. 2023 Oct 31. doi: 10.1111/bjh.19170.
     PubMed     Abstract available
     
     
     
212. PAN X, Chang Y, Ruan G, Wei F, et al
     Prognostic impact of FLT3-ITD mutation on NPM1(+) acute myeloid leukaemia patients and related molecular mechanisms.
     Br J Haematol. 2023;203:212-223.
     PubMed     Abstract available
     
     
     
213. MAHDI D, Spiers J, Rampotas A, Polverelli N, et al
     Updates on accelerated and blast phase myeloproliferative neoplasms: Are we making progress?
     Br J Haematol. 2023;203:169-181.
     PubMed     Abstract available
     
     
     
214. SEVERIN F, Mouawad N, Ruggeri E, Visentin A, et al
     Focal adhesion kinase activation by calcium-dependent calpain is involved in chronic lymphocytic leukaemia cell aggressiveness.
     Br J Haematol. 2023;203:224-236.
     PubMed     Abstract available
     
     
     
215. TRAVAGLINI S, Gurnari C, Antonelli S, Marchesi F, et al
     Functional characterization and response to FLT3 inhibitors in acute myeloid leukaemia with a non-canonical FLT3 mutation: A proof of concept.
     Br J Haematol. 2023;203:327-330.
     PubMed    
     
     
     
216. EADIE LN, Rehn JA, Schutz CE, Heatley SL, et al
     Case report: Rare case of donor cell-derived T-cell acute lymphoblastic leukaemia in a female patient after receiving an allo-transplant from her male sibling.
     Br J Haematol. 2023;203:282-287.
     PubMed     Abstract available
     
     
     September 2023
217. BRECCIA M, Saglio G
     Interferon in chronic myeloid leukaemia: Is it useful for treatment-free remission?
     Br J Haematol. 2023;202:1087-1088.
     PubMed     Abstract available
     
     
     
218. HADDAD FG, Kourie HR, Saleh K
     Moving away from chemotherapy in newly diagnosed Philadelphia chromosome-positive B-cell acute lymphoblastic leukaemia.
     Br J Haematol. 2023;202:1084-1086.
     PubMed     Abstract available
     
     
     
219. IRANI YD, Hughes A, Kok CH, Clarson J, et al
     Immune modulation in chronic myeloid leukaemia patients treated with nilotinib and interferon-alpha.
     Br J Haematol. 2023;202:1127-1136.
     PubMed     Abstract available
     
     
     
220. FENG H, Fu Y, Cui Z, Zhou M, et al
     Histone demethylase PHF8 facilitates the development of chronic myeloid leukaemia by directly targeting BCR::ABL1.
     Br J Haematol. 2023;202:1178-1191.
     PubMed     Abstract available
     
     
     
221. PESCHKE JC, Bergmann R, Mehnert M, Gonzalez Soto KE, et al
     FLT3-directed UniCAR T-cell therapy of acute myeloid leukaemia.
     Br J Haematol. 2023;202:1137-1150.
     PubMed     Abstract available
     
     
     
222. PASTORE F, Gittinger H, Raab S, Tschuri S, et al
     Acute megakaryoblastic leukaemia shows high frequency of chromosome 1q aberrations and dismal outcome.
     Br J Haematol. 2023;202:1165-1177.
     PubMed     Abstract available
     
     
     
223. XIE M, Lu Y, Ouyang G, Li X, et al
     Dasatinib plus prednisone as induction and consolidation for adults with Ph-positive acute lymphoblastic leukaemia: A single-arm, multicentre, phase 2 trial.
     Br J Haematol. 2023;202:1119-1126.
     PubMed     Abstract available
     
     
     
224. MATSUMOTO K, Kakazu N, Imataki O, Kondo A, et al
     Hairy cell leukaemia with an IGH-BRAF fusion gene.
     Br J Haematol. 2023;202:e67-e70.
     PubMed    
     
     
     
225. BELHADJ M, Burroni B, Kosmider O, Willems L, et al
     Clinico-biological features, treatment and prognosis of primary myeloid sarcoma: A French retrospective multi-centric observational study.
     Br J Haematol. 2023;202:e50-e53.
     PubMed    
     
     
     August 2023
226. KUSUDA M, Nakasone H, Yoshimura K, Okada Y, et al
     Gene expression and TCR amino acid sequences selected by HLA-A02:01-restricted CTLs specific to HTLV-1 in ATL patients.
     Br J Haematol. 2023;202:578-588.
     PubMed     Abstract available
     
     
     
227. LOKE J, Upasani V, Gaskell C, Fox S, et al
     Defective T-cell response to COVID-19 vaccination in acute myeloid leukaemia and myelodysplastic syndromes.
     Br J Haematol. 2023;202:498-503.
     PubMed     Abstract available
     
     
     
228. SARTOR C, Brunetti L, Audisio E, Cignetti A, et al
     A venetoclax and azacitidine bridge-to-transplant strategy for NPM1-mutated acute myeloid leukaemia in molecular failure.
     Br J Haematol. 2023;202:599-607.
     PubMed     Abstract available
     
     
     
229. BORRILL R, Poulton K, Kusyk L, Routledge A, et al
     Granulocyte transfusion during cord blood transplant for relapsed, refractory AML is associated with massive CD8(+) T-cell expansion, significant cytokine release syndrome and induction of disease remission.
     Br J Haematol. 2023;202:589-598.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.